The beneficial effects of allopurinol in cardiology practice: decrease in uric acid and vascular oxidative stress/ The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: A pilot study

References (1)

1. Shelmadine B, Bowden RG, Wilson RL, Beavers D, Hartman J. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg 2009; 9: 385-9. 2.Yiğiner Ö, Özcelik F, İnanç T, Aparcı M, Özmen N, Cingözbay BY, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome.Clin Res Cardiol 2008;97:334-40. 3.Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 1988; 37: 217-20. 4.Burnier M, Waeber B, Brunner HR. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens Suppl 1995; 13: S23-8. 5.Milionis HJ, Kakafika Al, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis Kl, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004; 148: 635-40. 6.George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-16. 7.Hare JM, Mangal B, Brown J, Fisher C, Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-9.